Hoffmann D, Rivenson A, Chung F L, Wynder E L
American Health Foundation, Valhalla, New York 10595.
Ann N Y Acad Sci. 1993 May 28;686:140-60. doi: 10.1111/j.1749-6632.1993.tb39169.x.
Tobacco smoking is causally associated with cancer of the lung, upper aerodigestive tract, pancreas, renal pelvis and urinary bladder. Tobacco chewers and especially snuff dippers face an increased risk for cancer of the oral cavity and pharynx. Although cessation of the tobacco habits is the only sure way to avoid an increased risk of tobacco-related cancers, certain modified products should be available to lower the incidence rates for cancer among those tobacco chewers and smokers who are unable to give up their tobacco habits. The modified cigarette has been the first approach toward the reduction of cancer risk. In the case of cancer of the lung, the long-term smoker of low-yield filter cigarettes has a risk reduction of 30-50% over that of the smoker of nonfilter cigarettes; however, the risk of filter cigarette smokers for cancer of the lung and cancer at other sites is still many times higher than that of the nonsmoker. A second modality is the application of natural or synthetic chemopreventive agents. Clinical studies with tobacco users have been primarily limited to the application of beta-carotene and retinoids. Although the data appear encouraging in respect to reducing early lesions in the oral cavity of tobacco chewers and smokers and in respect to second primaries in smokers, the benefits of beta-carotene and retinoids are gradually reversed upon withholding these micronutrients. It is understandable that activities in respect to chemopreventive agents in clinical trials on smokers are limited, since cessation of smoking alone leads within only a few years to a significant reduction of the cancer risk. Another reason for the limited interest in clinical trials on smokers may relate to the lack of laboratory data on the actual effects of chemopreventive agents in animals induced with tobacco-specific carcinogens. However, during the last few years, a number of natural or synthetic chemopreventive agents in animals induced with tobacco-specific carcinogens. However, during the last few years, a number of natural or synthetic chemopreventive agents have been tested in mice and rats which were treated with carcinogenic, tobacco-specific N-nitrosamines (TSNA). The results appear most encouraging in respect to lung tumor reduction. It is hoped that this type of research will gain in interest. Human data suggest that the fat content of the diet influences the cancer risk of smokers.(ABSTRACT TRUNCATED AT 400 WORDS)
吸烟与肺癌、上呼吸消化道癌、胰腺癌、肾盂癌和膀胱癌存在因果关联。嚼烟草者,尤其是吸鼻烟者,患口腔癌和咽癌的风险会增加。尽管戒除吸烟习惯是避免烟草相关癌症风险增加的唯一可靠方法,但对于那些无法戒除吸烟习惯的嚼烟草者和吸烟者,应提供某些改良产品以降低癌症发病率。改良香烟是降低癌症风险的首要方法。就肺癌而言,长期吸低焦油过滤嘴香烟的吸烟者比吸非过滤嘴香烟的吸烟者患癌风险降低30 - 50%;然而,过滤嘴香烟吸烟者患肺癌及其他部位癌症的风险仍比不吸烟者高很多倍。第二种方法是应用天然或合成的化学预防剂。对烟草使用者的临床研究主要局限于β - 胡萝卜素和类视黄醇的应用。尽管数据在减少嚼烟草者和吸烟者口腔早期病变以及吸烟者的第二原发癌方面看起来令人鼓舞,但停用这些微量营养素后,β - 胡萝卜素和类视黄醇的益处逐渐逆转。鉴于仅戒烟几年就能显著降低癌症风险,所以对吸烟者进行化学预防剂临床试验的活动有限是可以理解的。对吸烟者临床试验兴趣有限的另一个原因可能与缺乏关于化学预防剂对烟草特异性致癌物诱导的动物实际作用的实验室数据有关。然而,在过去几年里,一些天然或合成的化学预防剂已在经致癌性烟草特异性N - 亚硝胺(TSNA)处理的小鼠和大鼠身上进行了测试。就减少肺部肿瘤而言,结果看起来最令人鼓舞。希望这类研究能引起更多关注。人体数据表明饮食中的脂肪含量会影响吸烟者患癌风险。(摘要截选至400字)